The heparin contamination cases have highlighted the critical role of suppliers in the pharmaceutical industry. Consequently, the FDA is intensifying inspections of overseas production facilities and enforcing manufacturer accountability to guarantee that suppliers maintain compliance.

 

Under CGMP regulations (CFR Part 211.84), manufacturers can release raw materials or packaging items using the supplier’s certificate of analysis combined with visual verification of the product.

 

 

Establishing trust in a supplier requires systematic validation of their testing results at regular intervals. A structured supplier qualification program provides proof that the supplier can reliably supply safe materials. Continuous oversight and periodic evaluation are necessary to maintain trust, and it is ultimately the manufacturer’s duty to ensure that all suppliers remain qualified and dependable.